Mustang Bio, Inc. Cost of Revenue

Cost of Revenue of MBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cost of Revenue growth rates and interactive chart. Cost of revenue refers to the direct costs attributable to the production of the goods or supply of services by an entity. It is also commonly known as the “cost of goods sold (COGS)”. Cost of sales measures the cost of goods produced or services provided in a period by an entity. It includes the cost of the direct materials used in producing the goods, direct labor costs used to produce the good, along with any other direct costs associated with the production of goods. In case of services cost of sales includes the labor cost or salaries of the employees and other directly attributable costs. Cost of sales does not include indirect expenses such as distribution costs and marketing costs. It appears on the income statement and is deducted from the sales revenue for the calculation of gross profit (or gross margin).


Highlights and Quick Summary

  • Cost of Revenue for the quarter ending June 29, 2021 was $540 Thousand (a 10.2% increase compared to previous quarter)
  • Year-over-year quarterly Cost of Revenue increased by 27.06%
  • Annual Cost of Revenue for 2020 was $1.79 Million (a 30.48% increase from previous year)
  • Annual Cost of Revenue for 2019 was $1.37 Million (a 117.14% increase from previous year)
  • Annual Cost of Revenue for 2018 was $630 Thousand (a 31400.0% increase from previous year)
  • Twelve month Cost of Revenue ending June 29, 2021 was $1.94 Million (a 6.32% increase compared to previous quarter)
  • Twelve month trailing Cost of Revenue increased by 18.41% year-over-year
Trailing Cost of Revenue for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$1.94 Million $1.82 Million $1.74 Million $1.64 Million
Visit stockrow.com/MBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cost of Revenue of Mustang Bio, Inc.

Most recent Cost of Revenueof MBIO including historical data for past 10 years.

Interactive Chart of Cost of Revenue of Mustang Bio, Inc.

Mustang Bio, Inc. Cost of Revenue for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.54 $0.49
2020 $0.48 $0.43 $0.43 $0.4 $1.79
2019 $0.38 $1.37
2018 $0.63
2017 $0.0

Business Profile of Mustang Bio, Inc.

Sector: Healthcare
Industry: Biotechnology
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.